Isolated central nervous system progression on Crizotinib: An Achilles heel of non-small cell lung cancer with EML4-ALK translocation?

Cancer Biology and Therapy

Volumn 13, Issue 14, 2012, Pages 1376-1383

  Chun, Stephen G ^a   Choe, Kevin S ^a   Iyengar, Puneeth ^a   Yordy, John S ^a   Timmerman, Robert D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Anaplastic lymphoma kinase (ALK); Brain metastasis; Crizotinib; Non small cell lung cancer; Stereotactic radiosurgery

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CARBOPLATIN; CRIZOTINIB; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4 ANAPLASTIC LYMPHOMA KINASE FUSION PROTEIN; ERLOTINIB; PACLITAXEL; PEMETREXED; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CASE REPORT; CENTRAL NERVOUS SYSTEM METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG PENETRATION; DRUG RESPONSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING;

ADULT; BRAIN; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; TRANSLOCATION, GENETIC;

EID: 84870725524     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.22255     Document Type: Article

References (41)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212-36; PMID:21685461; http://dx.doi.org/10.3322/ caac.20121.
2. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol 2007; 25:561-70; PMID:17290066; http://dx.doi.org/10.1200/JCO.2006.06. 8015.
3. Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer--is it becoming a reality? Nat Rev Clin Oncol 2010; 7:401-14; PMID:20551945; http://dx.doi.org/10.1038/nrclinonc.2010.64.
4. Shaw AT, Solomon B, Kenudson MM. Crizotinib and testing for ALK. J Natl Compr Canc Netw 2011;9:1335-41; PMID:22157554.
5. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448:561-6; PMID:17625570; http://dx.doi.org/10.1038/ nature05945.
6. Martelli MP, Sozzi G, Hernandez L, Pettirossi V, Navarro A, Conte D, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 2009; 174:661-70; PMID:19147828; http://dx.doi.org/10.2353/ ajpath.2009.080755.
7. Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 2011; 17:2081-6; PMID:21288922; http://dx.doi.org/10.1158/1078- 0432.CCR-10-1591.
8. Mossé YP, Wood A, Maris JM. Inhibition of ALK signaling for cancer therapy. Clin Cancer Res 2009; 15:5609-14; PMID:19737948; http://dx.doi.org/10. 1158/1078-0432.CCR-08-2762.
9. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011; 12:1004-12; PMID:21933749; http://dx.doi.org/10. 1016/S1470-2045(11)70232-7.
10. Yang T, Liu H, Chen J. EML4-ALK fusion gene in lung cancer and its biological function. Zhongguo Fei Ai Za Zhi 2012; 15:112-6; PMID:22336240.
11. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363:1693-703; PMID:20979469; http://dx.doi.org/10.1056/NEJMoa1006448.
12. Kim YH, Mishima M. Maintenance chemotherapy for non-small-cell lung cancer. Cancer Treat Rev 2011; 37:505-10; PMID:21257270; http://dx.doi.org/10. 1016/j.ctrv.2010.12.007.
13. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al.; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-8; PMID:11784875; http://dx.doi.org/10.1056/NEJMoa011954.
14. Cui JJ, Tran-Dubé M, Shen H, Nambu M, Kung PP, Pairish M, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 2011; 54:6342-63; PMID:21812414; http://dx.doi.org/10.1021/jm2007613.
15. Yamazaki S, Vicini P, Shen Z, Zou HY, Lee J, Li Q, et al. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models. J Pharmacol Exp Ther 2012; 340:549-57; PMID:22129595; http://dx.doi.org/10.1124/ jpet.111.188870.
16. Joshi M, Jiang Y, Belani CP. Maintenance therapy for advanced non-small-cell lung cancer: switch versus continuation. Expert Opin Pharmacother 2012; 13:685-97; PMID:22404744; http://dx.doi.org/10.1517/14656566.2012.668530.
17. Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011; 29:e443-5; PMID:21422405; http://dx.doi.org/10.1200/JCO.2010.34. 1313.
18. Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R, et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res 2012; 72:100-11; PMID:22080568; http://dx.doi.org/10.1158/0008-5472.CAN-11-1403.
19. Soda M, Takada S, Takeuchi K, Choi YL, Enomoto M, Ueno T, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A 2008; 105:19893-7; PMID:19064915; http://dx.doi.org/10.1073/pnas.0805381105.
20. Li Y, Ye X, Liu J, Zha J, Pei L. Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors. Neoplasia 2011; 13:1-11; PMID:21245935.
21. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008; 14:4275-83; PMID:18594010; http://dx.doi.org/10.1158/ 1078-0432.CCR-08-0168.
22. Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 2009; 420:345-61; PMID:19459784; http://dx.doi.org/10.1042/BJ20090387.
23. Pulford K, Morris SW, Turturro F. Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol 2004; 199:330-58; PMID:15095281; http://dx.doi.org/10.1002/jcp.10472.
24. Perez-Pinera P, Chang Y, Deuel TF. Pleiotrophin, a multifunctional tumor promoter through induction of tumor angiogenesis, remodeling of the tumor microenvironment, and activation of stromal fibroblasts. Cell Cycle 2007; 6:2877-83; PMID:18156802; http://dx.doi.org/10.4161/cc.6.23.5090.
25. Bilsland JG, Wheeldon A, Mead A, Znamenskiy P, Almond S, Waters KA, et al. Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications. Neuropsychopharmacology 2008; 33:685-700; PMID:17487225; http://dx.doi.org/10. 1038/sj.npp.1301446.
26. Galetta D, Rossi A, Pisconti S, Colucci G. The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer. Expert Opin Ther Targets 2012; 16(Suppl 2):S45-54; PMID:22443113; http://dx.doi.org/10.1517/ 14728222.2011.642372.
27. Gandhi L, Jänne PA. Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. Clin Cancer Res 2012; 18:3737-42; PMID:22547770; http://dx.doi.org/10.1158/1078-0432.CCR-11-2393.
28. Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 1999; 45:427-34; PMID:10487566; http://dx.doi.org/10.1016/S0360-3016(99)00198-4.
29. Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011; 29:134-41; PMID:21041710; http://dx.doi.org/10.1200/JCO.2010.30.1655.
30. Doebele RC, Lu X, Sumey C, et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer 2012; 26; PMID:22260435.
31. Han C, Ma J, Zhao J, Zhou Y, Jing W, Zou H. EGFR mutations, gene amplification, and protein expression and KRAS mutations in primary and metastatic tumors of nonsmall cell lung cancers and their clinical implications: a meta-analysis. Cancer Invest 2011; 29:626-34; PMID:22011285; http://dx.doi.org/10.3109/07357907.2011.621914.
32. Kim HR, Shim HS, Chung JH, Lee YJ, Hong YK, Rha SY, et al. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer 2012; 118:729-39; PMID:21720997; http://dx.doi.org/10.1002/cncr.26311.
33. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, et al.; ALK Lung Cancer Study Group. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363:1734-9; PMID:20979473; http://dx.doi.org/10.1056/NEJMoa1007478.
34. Chi AS, Batchelor TT, Kwak EL, Clark JW, Wang DL, Wilner KD, et al. Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. J Clin Oncol 2012; 30:e30-3; PMID:22162573; http://dx.doi.org/10.1200/JCO.2011.38. 4586.
35. Zhang H, Wang Y, Chen Y, Sun S, Li N, Lv D, et al. Identification and validation of S100A7 associated with lung squamous cell carcinoma metastasis to brain. Lung Cancer 2007; 57:37-45; PMID:17418446; http://dx.doi.org/10.1016/j. lungcan.2007.02.020.
36. Gore E. RTOG 0214: a phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer. Clin Adv Hematol Oncol 2005; 3:625-6; PMID:16167048.
37. Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, et al.; EORTC Radiation Oncology Group and Lung Cancer Group. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007; 357:664-72; PMID:17699816; http://dx.doi.org/10.1056/NEJMoa071780.
38. Aupérin A, Arriagada R, Pignon JP, Le Péchoux C, Gregor A, Stephens RJ, et al.; Prophylactic Cranial Irradiation Overview Collaborative Group. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999; 341:476-84; PMID:10441603; http://dx.doi.org/10.1056/NEJM199908123410703.
39. Ma S, Xu Y, Deng Q, Yu X. Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer 2009; 65:198-203; PMID:19091441; http://dx.doi.org/10. 1016/j.lungcan.2008.10.028.
40. Kawabe T, Phi JH, Yamamoto M, Kim DG, Barfod BE, Urakawa Y. Treatment of brain metastasis from lung cancer. Prog Neurol Surg 2012; 25:148-55; PMID:22236676; http://dx.doi.org/10.1159/000331188.
41. Kim A, McCully C, Cruz R, Cole DE, Fox E, Balis FM, et al. The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. Invest New Drugs 2012; 30:524-8; PMID:21072558; http://dx.doi.org/10.1007/s10637-010-9585-1.